FLINT, Mich., Dec. 7, 2016 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty
Infusion Group, a new brand uniting five subsidiaries—American
Homecare Federation, At-Home IV Infusion Professional, BioRx,
MedPro Rx, and XAS Infusion Suites.
To learn more about Diplomat's specialty infusion services,
visit diplomat.is/specialty-infusion.
"As we continue to build on the work we have done, we are
excited to move forward with the launch of our new Diplomat
Specialty Infusion Group brand," said Diplomat CEO and Chairman
Phil Hagerman. "Together, our
combined resources allow us to continue to build upon our expertise
and services for patients with specialized needs."
Diplomat Specialty Infusion Group companies will continue their
focused services within their key areas of excellence,
including:
- Hemophilia and other bleeding disorders
- High-touch management for populations with rare bleeding
disorders and patients with hemophilia A, hemophilia B, inhibitors,
or von Willebrand disease.
- Hereditary angioedema (HAE)
- Specialized programs that guide HAE patients through their
medical journey.
- Alpha-1 antitrypsin deficiency
- Home infusion services specifically designed for patients with
alpha-1 antitrypsin deficiency.
- Immune globulin
- Home delivery and administration of immune globulin therapies,
including innovative patient and physician support programs.
- Parenteral and enteral nutrition
- Customized treatments and infusion support
"This brand opens a new door for us," said Phil Rielly, Diplomat vice president and
president of Diplomat Specialty Infusion Group. "Our patients are
our driving force. They are our motivation to continue pushing for
better therapies and educating on the industry. We are determined
to keep working and advocating under the new brand on their
behalf—to be the voice our patients don't always have."
To learn more about Diplomat, visit diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended December 31,
2015 and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases, including
oncology, immunology, hepatitis, multiple sclerosis, specialized
infusion therapy and many other serious or long-term conditions.
Diplomat opened its doors in 1975 as a neighborhood pharmacy with
one essential tenet: "Take good care of patients and the rest falls
into place." Today, that tradition continues—always focused on
improving patient care and clinical adherence. For more information
visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
John Louis, Director, Category
Management,
Specialty Infusion Group
610.924.5128 | jlouis@diplomat.is
Logo - http://photos.prnewswire.com/prnh/20140928/148820
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-unites-companies-under-specialty-infusion-group-brand-300374475.html
SOURCE Diplomat Pharmacy, Inc.